Abstract
Second generation electronic medication adherence monitors provide real-time data on pill bottle opening behavior. Feasibility, validity, and acceptability, however, have not been established. Med-eMonitor is a multi-compartment adherence device with reminder and education capacity that transmits data through a telephone connection. Monthly adherence levels were measured for 52 participants over approximately 3 months using the Med-eMonitor (unadjusted and adjusted for participant confirmed dosing) and unannounced pill counts. HIV RNA was assessed before and after the 3-month period. Acceptability of Med-eMonitor was determined. Over 92% of Med-eMonitor data was transmitted daily. Unannounced pill counts significantly correlated with adjusted Med-eMonitor adherence (r = 0.29, P = 0.04). HIV RNA significantly correlated with unannounced pill counts (r = −0.34, P = 0.02), and trended toward a significant correlation with unadjusted Med-eMonitor adherence (r = −0.26; P = 0.07). Most, but not all, participants liked using the Med-eMonitor. Med-eMonitor allows for real-time adherence monitoring and potentially intervention, which may be critical for prolonging treatment success.
Resumen
La segunda generación de monitores electrónicos de adherencia a la medicación proporcionan datos en tiempo real sobre el comportamiento de la apertura de la píldora botella. Viabilidad, validez y aceptación, sin embargo, no se han establecido. Med-eMonitor es un dispositivo de la adhesión de varios compartimentos con capacidad de recordatorio y la educación que transmite datos a través de una conexión telefónica. Los niveles de cumplimiento mensual se realizaron mediciones de 52 participantes para aproximadamente tres meses con el Med-eMonitor (no ajustados y ajustados para que el participante confirmado de dosificación) y píldora no anunciadas recuentos. ARN del VIH se evaluó antes y después del período de tres meses. La aceptabilidad de Med-eMonitor se determinó. Más del 92% de los datos de Med-eMonitor se transmitió diariamente. Píldora no anunciadas recuentos correlacionó significativamente con la adhesión ajustado Med-eMonitor (r = 0,29, P = 0,04). ARN del VIH se correlacionó significativamente con la píldora no anunciadas recuentos (r = −0.34, P = 0,02), y una tendencia hacia una correlación significativa con la adhesión sin ajustar Med-eMonitor ARN (r = −0,26, P = 0,07). La mayoría, pero no todos, los participantes le gustaba usar el Med-eMonitor. Med-eMonitor permite supervisar el cumplimiento en tiempo real y potencial de intervención, que puede ser crítico para prolongar el éxito del tratamiento.
Similar content being viewed by others
References
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.
Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.
Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139(10):810–6.
Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12(1):86–94.
Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187–91.
Petersen ML, Wang Y, van der Laan MJ, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007;45(7):908–15.
Bangsberg DR, Deeks SG. Spending more to save more: interventions to promote adherence. Ann Intern Med. 2010;152(1):54–6; W-13.
Bendle S, Velligan D, Mueller J, et al. The Med-eMonitor™ for improving adherence to oral medication in schizophrenia. Schizophr Bull. 2005;31(2):519.
Ruskin PE, Van Der Wende J, Clark CR, et al. Feasability of using the Med-eMonitor™ system in the treatment of schizophrenia: a pilot study. Drug Inf J. 2003;38:1–8.
Artinian N, Harden J, Kronenberg M, et al. Pilot study of a web-based compliance monitoring evice for patients with congestive heart failure. In Paper presented at international congress of schizophrenia research 2005; San Antoinio.
Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39(8):1190–8.
Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008;3(7):e2783.
Bangsberg D, Hecht F, Charlebois E, et al. Comparing objectives measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275–81.
Samet JH, Sullivan LM, Traphagen ET, et al. Measuring adherence among HIV-infected persons: is MEMS consummate technology? AIDS Behav. 2000;5(1):21–30.
Holden RJ, Karsh BT. The technology acceptance model: its past and its future in health care. J Biomed Inform. 2010;43(1):159–72.
Drews FA, Picciano P, Agutter J, Syroid N, Westenskow DR, Strayer DL. Development and evaluation of a just-in-time support system. Hum Factors. 2007;49(3):543–51.
Wyatt JC, Sullivan F. eHealth and the future: promise or peril? BMJ. 2005;331(7529):1391–3.
Kaplan WA. Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries? Glob Health. 2006;2:9.
Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115(8):632–41.
Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med. 2010;152(1):18–25.
Acknowledgments
The authors thank the National Institute of Mental Health (SBIR MH077502; RO1MH54907, K23MH087228, K01AI062435, K24MH87227) and the UCSF Clinical Translational Research Institute (UL1RR024131) for funding this research. They also thank Randy Dulin, Bruce Kehr, David Guzman, and all study participants. The manufactures of Med-eMonitor had no role in the analysis or preparation of the manuscript and the authors have no financial interest in Med-eMonitor.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haberer, J.E., Robbins, G.K., Ybarra, M. et al. Real-Time Electronic Adherence Monitoring is Feasible, Comparable to Unannounced Pill Counts, and Acceptable. AIDS Behav 16, 375–382 (2012). https://doi.org/10.1007/s10461-011-9933-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-011-9933-y